TY - JOUR
T1 - Safety of sentinel node biopsy in pregnant patients with breast cancer
AU - Gentilini, O.
AU - Cremonesi, M.
AU - Trifirò, G.
AU - Ferrari, M.
AU - Baio, S. M.
AU - Caracciolo, M.
AU - Rossi, A.
AU - Smeets, A.
AU - Galimberti, V.
AU - Luini, A.
AU - Tosi, G.
AU - Paganelli, G.
PY - 2004/9
Y1 - 2004/9
N2 - Background: Lymphoscintigraphy (LS) and sentinel lymph node biopsy (SLNB) have typically been contraindicated for pregnant patients diagnosed with breast cancer because they are considered unsafe. Patients and methods: Twenty-six premenopausal non-pregnant patients who were candidates for LS underwent peritumoral injection of ∼ 12 MBq of 99mTc-HSA nanocolloids. Static [15 min and 16h post-injection (p.i.)] and whole-body (16h p.i.) scintigraphic images were acquired. Activity concentration in the urine (0-2, 2-4, 4-8, 8-16h p.i.) was evaluated by a gamma-counter. Activity in the bloodstream was measured at 4 and 16h p.i. Thermoluminescent dosimeters (TLD) were placed, before tracer injection, on the injection site, between injection site and epigastrium (two points), and on the epigastrium, umbilicus and hypogastrium, and were removed before surgery. Results: Scintigraphic images showed no radiotracer concentration except in the injection site and in the sentinel node. In all patients, the total activity excreted within the first 16h was 99mTc-HAS), LS and SLNB can be performed safely during pregnancy, since the very low prenatal doses from this diagnostic procedure, when properly performed, do not significantly increase the risk of prenatal death, malformation or mental impairment.
AB - Background: Lymphoscintigraphy (LS) and sentinel lymph node biopsy (SLNB) have typically been contraindicated for pregnant patients diagnosed with breast cancer because they are considered unsafe. Patients and methods: Twenty-six premenopausal non-pregnant patients who were candidates for LS underwent peritumoral injection of ∼ 12 MBq of 99mTc-HSA nanocolloids. Static [15 min and 16h post-injection (p.i.)] and whole-body (16h p.i.) scintigraphic images were acquired. Activity concentration in the urine (0-2, 2-4, 4-8, 8-16h p.i.) was evaluated by a gamma-counter. Activity in the bloodstream was measured at 4 and 16h p.i. Thermoluminescent dosimeters (TLD) were placed, before tracer injection, on the injection site, between injection site and epigastrium (two points), and on the epigastrium, umbilicus and hypogastrium, and were removed before surgery. Results: Scintigraphic images showed no radiotracer concentration except in the injection site and in the sentinel node. In all patients, the total activity excreted within the first 16h was 99mTc-HAS), LS and SLNB can be performed safely during pregnancy, since the very low prenatal doses from this diagnostic procedure, when properly performed, do not significantly increase the risk of prenatal death, malformation or mental impairment.
KW - Breast cancer
KW - Lymphoscintigraphy
KW - Pregnancy
KW - Radiation protection
KW - Sentinel node
UR - http://www.scopus.com/inward/record.url?scp=4644320462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644320462&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdh355
DO - 10.1093/annonc/mdh355
M3 - Article
C2 - 15319240
AN - SCOPUS:4644320462
VL - 15
SP - 1348
EP - 1351
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 9
ER -